Alpha-9 Oncology

Alpha-9 Theranotics is a clinical-stage radiopharmaceutical company that develops differentiated and highly targeted radiopharmaceuticals aimed at improving cancer patient outcomes. Leveraging proprietary technology and deep expertise, Alpha-9 leads in the engineering of customized radiopharmaceuticals optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals using a systematic molecular design approach, offering significant potential for expansion into several validated oncology targets.